试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-13
Maternal and Fetal Outcome With Metformin Therapy for Obese Pregnant Women .
编号:NCT05554679登记状态:提前终止企业 / 申办者:Assiut University
药物 / 成分:Metformin
登记的停止原因(原文):financial issues
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-12
Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain
编号:NCT00930332登记状态:提前终止企业 / 申办者:NCIC Clinical Trials Group
药物 / 成分:methadone hydrochloride、questionnaire administration、management of therapy complications
登记的停止原因(原文):Poor accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-12
Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer
编号:NCT04460807登记状态:提前终止企业 / 申办者:Ente Ospedaliero Ospedali Galliera
药物 / 成分:Exemestane、Placebo oral tablet
登记的停止原因(原文):low accrual, COVID 19 emergency and the modification of the standard of care for ovarian cancer treatment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-12
A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
编号:NCT04461600登记状态:提前终止企业 / 申办者:Ayala Pharmaceuticals, Inc,
药物 / 成分:AL101
登记的停止原因(原文):Sponsor's decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-12
Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia
编号:NCT04956042登记状态:提前终止企业 / 申办者:CicloMed LLC
药物 / 成分:Fosciclopirox、Fosciclopirox + Cytarabine
登记的停止原因(原文):Discontinued
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-12
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
编号:NCT05641324登记状态:提前终止企业 / 申办者:Anaveon AG
药物 / 成分:ANV419、Lenalidomide with low-dose dexamethasone、Daratumumab
登记的停止原因(原文):The study was ended due to a lack of recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-09
Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART
编号:NCT03198559登记状态:提前终止企业 / 申办者:University of Melbourne
药物 / 成分:Disulfiram, (National Drug Code) NDC 0378-4141-01、Vorinostat, NDC 00006-0568-40
登记的停止原因(原文):A re-evaluation of research risks to participants were greater than originally anticipated
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-09
Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)
编号:NCT03493568登记状态:提前终止企业 / 申办者:IRCCS San Raffaele
药物 / 成分:Genvoya 150Mg-150Mg-200Mg-10Mg Tablet、Dolutegravir 50 mg plus one RTI
登记的停止原因(原文):The futility analysis on 24-week results estimated that there was only 2% probability of verifying the study hypothesis of a higher proportion pat. with no residual viremia through 48w in arm E/C/F/TAF
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-09
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
编号:NCT04171284登记状态:提前终止企业 / 申办者:Sinocelltech Ltd.
药物 / 成分:SCT-I10、Docetaxel、Placebo
登记的停止原因(原文):Strategy adjustments, independent of the safety and efficacy of the trial medication
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-09
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
编号:NCT04409223登记状态:提前终止企业 / 申办者:Jiangsu HengRui Medicine Co., Ltd.
药物 / 成分:Famitinib capsules、Sunitinib Capsules
登记的停止原因(原文):R\&D strategy adjustment
查看官方原始记录 ↗